<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05053685</url>
  </required_header>
  <id_info>
    <org_study_id>OSA_Mets</org_study_id>
    <nct_id>NCT05053685</nct_id>
  </id_info>
  <brief_title>Metanephrines in Obstructive Sleep Apnoea</brief_title>
  <official_title>Utility of Plasma and Urine Metanephrines in the Diagnosis of Phaeochromocytoma in Patients With Obstructive Sleep Apnoea</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Changi General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Changi General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although most patients have essential (unexplained) hypertension, some patients have a&#xD;
      treatable underlying condition. One such condition is phaeochromocytoma, a tumour that&#xD;
      produces excessive stress hormones. Left undiagnosed, patients may develop a hypertensive&#xD;
      crisis that can be fatal. Measurements of stress hormones (both 24-hour urine collection and&#xD;
      morning blood tests) are highly sensitive for detecting these tumours. However, these stress&#xD;
      hormones may also be elevated in obstructive sleep apnoea (OSA) which affects 1 in 5 adults.&#xD;
&#xD;
      The investigators hypothesize that in patients with OSA, blood tests will be better than&#xD;
      24-hr urine tests at ruling out a tumour. If this is confirmed, then OSA patients with&#xD;
      suspected phaeochromocytoma could be investigated with a morning blood test instead of a&#xD;
      traditional urine test, reducing unnecessary additional tests and patient anxiety.&#xD;
&#xD;
      In this single site study, the investigators plan to recruit 70 patients undergoing&#xD;
      polysomnography. 24hr urine and bloods will be measured. Patients with elevated hormone&#xD;
      levels will undergo imaging to rule out a tumour.&#xD;
&#xD;
      The primary outcome will be the accuracy of each test in ruling out a tumour. The secondary&#xD;
      outcomes will be the relationship between stress hormone level and severity of OSA, which may&#xD;
      help to explain the increased cardiovascular risk in patients with OSA, and the change in&#xD;
      stress hormone level with treatment for OSA&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 29, 2020</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Urine and plasma metanephrines</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of 24 hours urine metanephrines</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Urine and plasma metanephrines</measure>
    <time_frame>1 year</time_frame>
    <description>Measurement of plasma metanephrines</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Relationship between metanephrine level and severity of OSA</measure>
    <time_frame>1 year</time_frame>
    <description>comparison of metanephrine level and severity of OSA as dertermined by sleep study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in metanephrine levels with treatment for OSA</measure>
    <time_frame>1 year</time_frame>
    <description>Change in plasma and urine metanephrine levels during treatment for OSA</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Pheochromocytoma</condition>
  <condition>Obstructive Sleep Apnea</condition>
  <condition>Catecholamine; Secretion</condition>
  <arm_group>
    <arm_group_label>Obstructive Sleep Apnoea (OSA)</arm_group_label>
    <description>Subjects with OSA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Elevated Urine Metanephrines</arm_group_label>
    <description>Subjects with elevated metanephrines</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Measurement of Urine and plasma metanephrines</intervention_name>
    <description>Measurement of Urine and plasma metanephrines</description>
    <arm_group_label>Elevated Urine Metanephrines</arm_group_label>
    <arm_group_label>Obstructive Sleep Apnoea (OSA)</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients attending for sleep studies for evaluation of OSA&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 21-70 years attending for a sleep study to evaluate for OSA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medications that can cause changes in metanephrine levels&#xD;
&#xD;
          -  Other factors that can cause changes in metanephrine levels&#xD;
&#xD;
          -  Renal impairment (eGFR &lt; 60ml/min)&#xD;
&#xD;
          -  Other serious medical conditions&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas King, MD</last_name>
    <phone>+6569365651</phone>
    <email>thomas.king@singhealth.com.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>Changi General Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>529889</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas King, MD</last_name>
      <phone>+6569365651</phone>
      <email>thomas.king@singhealth.com.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 12, 2021</study_first_submitted>
  <study_first_submitted_qc>September 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 22, 2021</study_first_posted>
  <last_update_submitted>September 14, 2021</last_update_submitted>
  <last_update_submitted_qc>September 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pheochromocytoma</mesh_term>
    <mesh_term>Apnea</mesh_term>
    <mesh_term>Sleep Apnea Syndromes</mesh_term>
    <mesh_term>Sleep Apnea, Obstructive</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

